2NAKAGAWA K,TAMURA T,NEGORO S,KUDOH S,YAMAMOTO N,YAMAMOTO N,ET AL.PHASE I PHARMACOKINETIC TRIAL OF THE SELECTIVE ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR GEFITINIB (’IRESSA’, ZD1839) IN JAPANESE PATIENTS WITH SOLID MALIGNANT TUMORS[].Annals of Oncology.2003
3HERBST RS.DOSE-COMPARATIVE MONOTHERAPY TRIALS OF ZD1839 IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS[].Seminars in Oncology.2003
4PAEZ JG,JANNE PA,LEE JC,TRACY S,GREULICH H,GABRIEL S,ET AL.EGFR MUTATIONS IN LUNG CANCER: CORRELATION WITH CLINICAL RESPONSE TO GEFITINIB THERAPY[].Science.2004
5HAURA EB.TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER: A REVIEW OF CURRENT RANDOMIZED CLINICAL TRIALS AND AN EXAMINATION OF EMERGING THERAPIES[].Cancer Control.2001
6KRIS MG,NATALE RB,HERBST RS,LYNCH TJ JR,PRAGER D,BELANI CP,ET AL.EFFICACY OF GEFITINIB, ANINHIBITOR OF THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN SYMPTOMATIC PATIENTS WITH NON-SMALL CELL LUNG CANCER: A RANDOMIZED TRIAL[].The Journal of The American Medical Association.2003
7CELLA D.IMPACT OF ZD1839 ON NON-SMALL CELL LUNG CANCER-RELATED SYMPTOMS AS MEASURED BY THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-LUNG SCALE[].Seminars in Oncology.2003
8FUKUOKA M,YANO S,GIACCONE G,TAMURA T,NAKAGAWA K,DOUILLARD JY,ET AL.MULTI-INSTITUTIONAL RANDOMIZED PHASE II TRIAL OF GEFITINIB FOR PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER[].Journal of Clinical Oncology.2003
